Anti-addictive Drug Vaccine Platform
|
|
- Cornelius Oliver
- 6 years ago
- Views:
Transcription
1 Anti-addictive Drug Vaccine Platform Brian J. Kelly, Ph.D. Cornell Center for Technology Enterprise and Commercialization June 21, 2012
2 Winning the War
3 Strategy Use Gene Transfer Vectors to Develop Effective Antiaddiction Vaccines Gene transfer vaccine At risk for addiction Generate immunity against addictive drug
4 Why Use Viral Gene Transfer Vectors as Platforms? Effective adjuvants Delete genes to render replication incompetent Rapid induction of immunity Can deliver monoclonal antibodies Can generate active immunity against small molecules conjugated to surface proteins Enhance host defenses Viral gene transfer vector
5 Drug Addiction Market - world-wide problem for which there is no preventive treatment or effective therapy Strategy develop vaccines directed against preventing addictive drugs from reaching their receptors on brain cells Challenge all addictive drugs are small molecules not seen by the immune system Cocaine N O O O O
6 Platform Strategies for Vaccines for Addictive Drugs Active vaccine Passive vaccine Addictive drug Light chain Heavy chain Anti-addictive drug monoclonal antibody Anti-addictive drug AAV-based passive vaccine Anti-addictive drug adenovirus-based active vaccine
7 Platform Technology Couple Addictive Drugs to Adenovirus Capsid Proteins Adenoviruses are highly immunogenic By coupling a small addictive drug (or its analog) to the adenovirus capsid proteins, the immune system will think the addictive drug is immunogenic Antibodies generated against the addictive drug will prevent it from reaching the brain Addictive drug Adenovirus
8 Design of a Disrupted Adenovirus- based Anti-cocaine Vaccine to Treat Cocaine Addiction dad5gnc vaccine Conjugation of a cocaine analog to heat and detergent- disrupted adenovirus will present the hapten as an immunogen to evoke high titer anti-cocaine immunity N O Linker O O O GNC cocaine analog Activate with crosslinker Mix GNC with disrupted Ad5 E1 - E3 - Ad5 Disrupt with SDS at 56 C, 45 sec Fiber Hexon Penton base dad5gnc
9 dad5gnc-mediated Induction of High Titer Anti-GNC Antibodies in Mice dad5gnc dad5gnc 1 st boost 2 nd boost Balb/c n=20 Intramuscular Boost at 3 and 6 wk with dad5gnc Evaluate Serum anti-cocaine antibody titer Serum anti-gnc antibody titer Time post-injection (wk)
10 Reduction in Ratio of Blood to Brain Cocaine Levels in Mice Challenged Intravenously with Cocaine Cocaine (ng/g brain, ) Naive dad5gnc n = 4 Intravenous 3 H-cocaine (2.5 mg) Sacrifice after 1 min Ratio blood / brain Cocaine (ng/ml serum, ) Evaluate Amount of cocaine in brain and blood 0 0 Brain Serum Brain Serum Naive dad5gnc100 dad5gnc vaccinated mice retain cocaine in the blood with a 10-fold difference in blood to brain ratio relative to naive mice
11 Cocaine-induced Locomotor Activity of Naive and dad5gnc-vaccinated Mice Naive + PBS Naive + cocaine (25 µg, IV) dad5gnc + cocaine (25 µg, IV) Naive + cocaine (50 µg, IV) dad5gnc + cocaine (50 µg, IV)
12 Cumulative ambulatory time (sec) dad5gnc Vaccine-mediated Reduction of Cocaine-induced Hyperactive Activity 200 Cocaine 50 µg IV Naive mice + cocaine dad5gnc + cocaine dad5gnc + PBS Naive mice + PBS Time post-injection (min)
13 Total distance traveled (cm x10 3 /10 min) Persistence of Vaccine-mediated Abrogation of Cocaine-induced Hyperactivity 5.0 Cocaine 50 µg 4.0 Naive + cocaine dad5gnc + PBS Naive + PBS Time of repeated challenge (wk) dad5gnc + cocaine
14 Anti-cocaine Antibody Titers in dad5gnevaccinated Non-human Primates dad5gne 100 µg, intramuscular 0-35 wk Evaluate Rhesus macaque n = 6 Serum anti-cocaine antibody titers (ELISA) Serum anti-cocaine antibody titer dad5gne Limit of detection K d = 80 mm Controls, not vaccinated Time post-injection (wk)
15 Change in blood pressure (mmhg) Ability of dad5gne Vaccination to Prevent the Cocaine-induced Cardiovascular Phenotype dad5gne 100 mg, intramuscular A. Control Cocaine 10 Rhesus macaque 0 systolic diastolic 10 wk cocaine 1 mg/kg, IV B. dad5gne vaccinated 30 Cocaine 20 Evaluate Blood pressure Time (min)
16 Biology of Cocaine Action 1 Cocaine blocks the dopamine transporter Binding sites for dopamine and cocaine overlap in the transmembrane segments of the transporter Transmitting neuron Dopamine packaged in vesicles Result dopamine accumulation in synaptic clefts Enhanced, prolonged postsynaptic dopaminergic signaling of dopamine receptor in the receiving neurons Dopamine transporter functioning normally Dopamine receptors Receiving neuron Dopamine transporter blocked by cocaine Cocaine The cocaine high in humans requires >47% dopamine transporter occupancy by cocaine 1 1 Volkow et al, Nature 1997; 386: 827
17 Question Does the dad5gne anti-cocaine vaccine prevent cocaine from reaching its receptors in the brain?
18 Imaging Dopamine Transporter Occupancy with 11 C-PE2i 11 C-PE2i - cocaine analog which binds with high selectivity to the dopamine transporter Use 11 C-PE2i as a radiolabel for positron emission tomography imaging of the dopamine transporter Cocaine N O O O O CH 3 Cocaine displaces 11 C-PE2i in a dose-dependent manner, permitting quantitative assessment of cocaine occupancy of the dopamine transporter 11 C-PE2i I N O O O O 11 CH 3 CH 3
19 11 C-PE2i Imaging of the Dopamine Transporter in the Caudate and Putamen Non-human primate Rhesus macaque Caudate Putamen
20 Efficacy of dad5gne in Preventing Cocaine from Reaching CNS Dopamine Transporters dad5gne 100 mg, intramuscular No cocaine Pre-vaccination + Cocaine Rhesus macaque PET imaging of the dopamine transporter with 11 C-PE2i No cocaine 67% cocaine occupancy Post-vaccination + Cocaine Evaluate Caudate and putamen labeling with 11 C- PE2i before and after cocaine administration (1 mg/kg, intravenous) 23% cocaine occupancy
21 Conclusion Based on the knowledge that >47% of the CNS dopamine transporters have to be occupied by cocaine for humans to get a cocaine high, these studies in nonhuman primates suggest that the dad5gne vaccine should be effective as an anti-cocaine vaccine
22 How Many People Smoke Worldwide? Estimated 1.3 billion people smoke worldwide 5.4 million deaths/yr, estimated to increase to 10 million/yr in death every 6.5 sec 33-50% of all smokers die of a smoking related death Current strategies to help smokers quit are ineffective with an 80% recidivism rate Nicotine in the principal addictive component of cigarettes, mediating its effect through CNS nicotinic cholinergic receptors Immunotherapy against nicotine is a potential means to block nicotine from reaching the CNS
23 Anti-Nicotine Passive Immunization Hypothesis If high levels of anti-nicotine monoclonal antibody could be expressed via an adeno-associated virus (AAV) gene expression vector, it should be possible to induce persistent passive immunization that would prevent nicotine from reaching its receptors in the brain
24 Questions Can an AAV vector mediate persistent expression of high levels of a high affinity monoclonal anti-nicotine antibody? Will the anti-nicotine antibody expressed by the AAV vector sequester intravenous administered nicotine in the blood and shield the brain? Will anti-nicotine immunotherapy block nicotine-induced cardiovascular and behavioral responses upon challenge with nicotine?
25 Generation of an Adeno-associated Virus Gene Transfer Vector Coding for an Anti-nicotine Monoclonal Antibody Light Chain Igκ Heavy Chain IgG1 Anti-nicotine antibody (NIC9D9) Expression cassette ITR CAG Heavy chain AAVantiNic Furin 2A Light chain (A n ) ITR
26 Serum anti-nicotine antibody titer (µg/ml) Persistence of AAVantiNic-directed Expression of an anti-nicotine Monoclonal Antibody AAVantiNic (10 11 genome copies) 10 4 IV 10 3 AAVantiNic C57Bl/6 n=5 Evaluate Serum anti-nicotine antibody titers (ELISA) wk K d = 43 ± 20 nmol/l Time (wk) Limit of detection AAVcontrol
27 AAVantiNic Shields the Brain from Systemic Nicotine Nicotine (ng/g brain) Nicotine (ng/ml serum) AAVantiNic (10 11 genome copies) A. Brain IV 60 4 months Nicotine (0.03 mg/kg, IV) 1 min C57Bl/6 n= B. Serum Assess Brain and blood 3 H- nicotine levels Naive AAVantiNic
28 Vertical activity (sec) Total distance (m) AAVantiNic Immunization Blocks Nicotineinduced Hypo-locomotion AAVantiNic (10 11 genome copies) 7 wk Nicotine (0.5 mg/kg, subcutaneous) C57Bl/6 n=10 Assess Cumulative distance traveled (15 min) Vertical activity time (15 min) A. Total distance Time post-injection (min) B. Vertical activity AAVantiNic + nicotine Naive + PBS Naive + nicotine AAVantiNic + nicotine Naive + PBS Naive + nicotine Time in chamber (min)
29 Mean arterial blood pressure (mmhg) Heart rate (bpm) AAVantiNic Prevents Cardiovascular Effects of Nicotine AAVantiNic (10 11 genome copies) A. Heart rate Nicotine * 5 wk Nicotine (1.0 mg/kg, subcutaneous) C57Bl/6 n=4 Evaluate Heart rate and mean arterial pressure B. Blood pressure Nicotine * AAVantiNic + nicotine AAVantiNic + PBS AAVcontrol + nicotine AAVantiNic + nicotine AAVantiNic + PBS AAVcontrol + nicotine Time (min)
30 Summary Passive immunization with AAVantiNic mediates persistent expression of high levels of a high affinity anti-nicotine antibody Upon challenge, AAVantiNic immunized mice retain nicotine in the blood and shield the brain from nicotine AAVantiNic blocks nicotine-mediated alterations in locomotor activity and cardiovascular effects AAV-based vaccines coding for a high affinity anti-nicotine monoclonal antibody may be a useful strategy to help nicotine-addicted subjects discontinue cigarette smoking
31 Anti-addictive Drug Vaccines Efficacious in experimental animal models Extensive clinical experience with adenoviruses Manufacturing capacity Versatile platform Pending patents Big market Clear path to clinical trials but need $$$! How can you help?
32 Vaccines to Shield the CNS from Addictive Drugs Addictive drug
The Challenge and Approach of Developing a Novel Anti-Nicotine Vaccine. Heather L. Davis, PhD Pfizer Vaccine Immunotherapeutics Ottawa, Canada
The Challenge and Approach of Developing a Novel Anti-Nicotine Vaccine Heather L. Davis, PhD Pfizer Vaccine Immunotherapeutics Ottawa, Canada Disclaimer This work was funded by Pfizer and was conducted
More informationArming the Oncolytic Virus Enadenotucirev to Develop Tumor-Localized Combination Immunotherapeutics. Charles Q. Morris MBChB MRCP(UK)
Arming the Oncolytic Virus Enadenotucirev to Develop Tumor-Localized Combination Immunotherapeutics Charles Q. Morris MBChB MRCP(UK) 1 Enadenotucirev (EnAd): Developed using directed evolution EnAd Start
More informationCloudbreak. March Cidara Therapeutics
Cloudbreak March 2019 Cidara Therapeutics 2019 0 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities
More informationCloudbreak. January Cidara Therapeutics
Cloudbreak January 2019 Cidara Therapeutics 2019 0 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities
More informationChoosing Between Lentivirus and Adeno-associated Virus For DNA Delivery
Choosing Between Lentivirus and Adeno-associated Virus For DNA Delivery Presenter: April 12, 2017 Ed Davis, Ph.D. Senior Application Scientist GeneCopoeia, Inc. Outline Introduction to GeneCopoeia Lentiviral
More informationThis training module is required for all personnel listed on an IBC protocol that describes work utilizing viral vectors (both replication competent
This training module is required for all personnel listed on an IBC protocol that describes work utilizing viral vectors (both replication competent and incompetent) regardless of the biosafety level used
More informationA Novel Recombinant Virus Reagent Products for Efficient Preparation Of Hepatitis B Animal Models
About FivePlus Beijing FivePlus Molecular Medicine Institute was established in 2005. The company has been dedicating itself to continuous innovation of viral vectors. The meaning of FivePlus is based
More informationFeb 11, Gene Therapy. Sam K.P. Kung Immunology Rm 417 Apotex Center
Gene Therapy Sam K.P. Kung Immunology Rm 417 Apotex Center Objectives: The concept of gene therapy, and an introduction of some of the currently used gene therapy vector Undesirable immune responses to
More informationIntroduction. In the past 15 years, several technological advancements have open new perspectives and applications in the field of vaccinology.
Introduction In the past 15 years, several technological advancements have open new perspectives and applications in the field of vaccinology. - Genomics: fasten antigen discovery for complex pathogens
More informationFoot and Mouth Disease Vaccine Research and Development in India
Foot and Mouth Disease Vaccine Research and Development in India R.Venkataramanan Indian Veterinary Research Institute, Hebbal, Bangalore 560 024 Foot and Mouth Disease in India Present Status Large Susceptible
More informationAnatomy of a Neuron. Copyright 2000 by BSCS and Videodiscovery, Inc. Permission granted for classroom use. Master 2.1
Anatomy of a Neuron Master 2.1 Neurons Interact With Other Neurons Through Synapses Master 2.2 How Do Neurons Communicate? 1 2 3 4 5 6 Master 2.3 Neurons Communicate by Neurotransmission Neurons communicate
More informationLQB383 Testbank. Week 8 Cell Communication and Signaling Mechanisms
LQB383 Testbank Week 8 Cell Communication and Signaling Mechanisms Terms to learn match the terms to the definitions --------------------------------------------------------------------------------------------------------------------------
More informationTrends in vaccinology
Trends in vaccinology Mathieu Peeters, MD Joint Conference of European Human Pharmacological Societies and Joint Conference of European Human Pharmacological Societies and 20th Anniversary of AGAH March
More informationModeling Excitatory and Inhibitory Chemical Synapses
In review, a synapse is the place where signals are transmitted from a neuron, the presynaptic neuron, to another cell. This second cell may be another neuron, muscle cell or glandular cell. If the second
More informationPrinciples of Vaccination
Immunology and Vaccine-Preventable Diseases Immunology is a complicated subject, and a detailed discussion of it is beyond the scope of this text. However, an understanding of the basic function of the
More informationRecombinant adeno-associated virus vectors induce functionally impaired transgene product specific CD8 + T cells in mice
Recombinant adeno-associated virus vectors induce functionally impaired transgene product specific CD8 + T cells in mice Shih-Wen Lin,, Marcio O. Lasaro, Hildegund C.J. Ertl J Clin Invest. 2007;117(12):3958-3970.
More informationBiotechnology-Based Vaccines. Dr. Aws Alshamsan Department of Pharmaceutics Office: AA87 Tel:
Biotechnology-Based Vaccines Dr. Aws Alshamsan Department of Pharmaceutics Office: AA87 Tel: 4677363 aalshamsan@ksu.edu.sa Objectives of this lecture By the end of this lecture you will be able to: 1.
More informationVirus Structure. Characteristics of capsids. Virus envelopes. Virion assembly John Wiley & Sons, Inc. All rights reserved.
Virus Structure Characteristics of capsids Virus envelopes Virion assembly Capsids package viral genomes and transmit them to a new host cell Capsid rigid, symmetrical container composed of viral protein
More informationNeuroimaging of Addiction
Neuroimaging of Addiction Sang Eun Kim, MD, PhD Department of Nuclear Medicine Seoul National University College of Medicine Seoul, Korea SNUBH Preclinical and Clinical Molecular Imaging Center (SNUBH-MIC)
More informationWhat s New for People Living With HoFH
What s New for People Living With HoFH (Homozygous Familial Hypercholesterolemia)? An innovative experimental gene therapy treatment for HoFH Learn about the ongoing gene therapy clinical trial in HoFH
More informationViral Vectors In The Research Laboratory: Just How Safe Are They? Dawn P. Wooley, Ph.D., SM(NRM), RBP, CBSP
Viral Vectors In The Research Laboratory: Just How Safe Are They? Dawn P. Wooley, Ph.D., SM(NRM), RBP, CBSP 1 Learning Objectives Recognize hazards associated with viral vectors in research and animal
More informationDavid L. Bartlett, M.D. University of Pittsburgh
A Phase I Dose-Escalation Trial of vvdd- CDSR (Double-Deleted Vaccinia Virus Plus CD/SMR) Administered by Intratumoral Injection in Patients with Superficial Injectable Tumors David L. Bartlett, M.D. University
More informationModeling Neurotransmission and Drugs. CHM 108 Lab. Spring Dr. Angela King
Modeling Neurotransmission and Drugs CHM 18 Lab Spring 28 Dr. Angela King Part A: How does the brain communicate? The human brain is the most complex organ in the body. This three-pound mass of gray and
More informationEnhancing the efficacy of a nicotine vaccine
Enhancing the efficacy of a nicotine vaccine A DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY Katherine E. Cornish IN PARTIAL FULFILLMENT OF THE REQUIREMENTS
More informationNanoparticulate Vaccine Design: The VesiVax System
Nanoparticulate Vaccine Design: The VesiVax System Gary Fujii, Ph.D. President and CEO Molecular Express, Inc. May 16, 2006 Orlando, Florida Influenza Each year up to 20% of the world's population contracts
More informationCombinatorial Vaccines for AIDS and other Infectious Diseases
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Combinatorial Vaccines for AIDS
More informationBody control systems. Let s start at the top: the human brain. The Cerebrum. The human brain. What parts of your brain are you using right now?
What parts of your brain are you using right now? Body control systems Quick Sends message directly to target organ Endocrine system Frontal lobe Parietal lobe Movement and conscious thought; Frontal speech
More information19 Viruses BIOLOGY. Outline. Structural Features and Characteristics. The Good the Bad and the Ugly. Structural Features and Characteristics
9 Viruses CAMPBELL BIOLOGY TENTH EDITION Reece Urry Cain Wasserman Minorsky Jackson Outline I. Viruses A. Structure of viruses B. Common Characteristics of Viruses C. Viral replication D. HIV Lecture Presentation
More informationLESSON 4.6 WORKBOOK. Designing an antiviral drug The challenge of HIV
LESSON 4.6 WORKBOOK Designing an antiviral drug The challenge of HIV In the last two lessons we discussed the how the viral life cycle causes host cell damage. But is there anything we can do to prevent
More informationUpdate on influenza vaccination using microneedle delivery
Mark Prausnitz serves as a consultant and is an inventor on patents licensed to companies developing products related to this presentation. This potential conflict of interest is being managed by Georgia
More informationViral reproductive cycle
Lecture 29: Viruses Lecture outline 11/11/05 Types of viruses Bacteriophage Lytic and lysogenic life cycles viruses viruses Influenza Prions Mad cow disease 0.5 µm Figure 18.4 Viral structure of capsid
More informationCurrent Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a Case Study
Note: I have added some clarifying comments to the slides -- please click on Comments under View to see them. Current Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a
More informationchapter 17: specific/adaptable defenses of the host: the immune response
chapter 17: specific/adaptable defenses of the host: the immune response defense against infection & illness body defenses innate/ non-specific adaptable/ specific epithelium, fever, inflammation, complement,
More information11/15/2011. Outline. Structural Features and Characteristics. The Good the Bad and the Ugly. Viral Genomes. Structural Features and Characteristics
Chapter 19 - Viruses Outline I. Viruses A. Structure of viruses B. Common Characteristics of Viruses C. Viral replication D. HIV II. Prions The Good the Bad and the Ugly Viruses fit into the bad category
More informationResearch Activities AMA-1 CSP
Research Activities Project 1 - CD1d-binding NKT Stimulating Glycolipids as an Adjuvant for Malaria/HIV Vaccines We aimed to identify a unique glycolipid which can exert potent stimulatory activity on
More informationA Quarterly Update on HIV Prevention Research. Vol. 8 No. 2
What is it? What could it do? Key Facts Antibodies Passive immunization is the transfer of pre-made antibodies to a person. Passive immunization using today's pre-made antibodies can involve infusion delivered
More informationRaze-On. Tobacco 101
Raze-On Tobacco 101 Key Messages Most people don t use tobacco Tobacco kills Nicotine is addictive The tobacco industry targets youth Tobacco Use in Teens 80% of adult smokers start before the age of 18
More informationPROCEDURE Follow the instructions as you proceed through the Click and Learn, and answer the questions in the spaces provided.
ABOUT THIS WORKSHEET This worksheet complements the Click and Learn developed in conjunction with the 2016 documentary, Spillover: Zika, Ebola & Beyond (http://www.hhmi.org/biointeractive/virusexplorer).
More informationGastroenteritis and viral infections
Gastroenteritis and viral infections A Large number of viruses are found in the human gut; these include some that are associated with gastroenteritis Rotaviruses Adenoviruses 40/41 Caliciviruses Norwalk-like
More informationDevelopment of MVA-VLP Vectors for Cancer Immunotherapy
Farshad Guirakhoo, PhD fguirakhoo@geovax.com 678-384-7229 Development of MVA-VLP Vectors for Cancer Immunotherapy Executive Summary Cancer is the second most common cause of death in the US, exceeded only
More informationThe Role of NEUROIMAGING In Diagnostic and Clinical Practice
The Role of NEUROIMAGING In Diagnostic and Clinical Practice ADHD Schizophrenia Autism Addiction Altzheimer s Disease Nora D. Volkow, M.D. Director National Institute on Drug Abuse National Institutes
More informationSmoking and Drinking
January 2018 E-bulletin no. 14 Smoking and Drinking The 14th e-bulletin of The Observatory of The General Secretariat for Gender Equality (GSGE) deals with the thematic area of Smoking and Drinking. More
More information<20 <20 <20 < <20 <20 <20 <20. Mock
Cross-Lineage Neutralization PRNT 80 Titers Asian Asian West African Indian Ocean Group NHP Strain 181/25 Strain 99659 Strain 37997 Strain LR 142590 80 80 20 40 EILV/CHIKV 150844 640 640 160 320 Mock 150849
More informationChapter 6- An Introduction to Viruses*
Chapter 6- An Introduction to Viruses* *Lecture notes are to be used as a study guide only and do not represent the comprehensive information you will need to know for the exams. 6.1 Overview of Viruses
More informationMonkey Models of Cocaine Abuse: Sex, Drugs and the Environment
Monkey Models of Cocaine Abuse: Sex, Drugs and the Environment Michael A. Nader, Ph.D. Departments of Physiology & Pharmacology and Radiology Harwood, 2000; Surgeon General s Report, 2004; ONDCP, 2004;
More informationThird line of Defense
Chapter 15 Specific Immunity and Immunization Topics -3 rd of Defense - B cells - T cells - Specific Immunities Third line of Defense Specific immunity is a complex interaction of immune cells (leukocytes)
More informationExperimental Therapeutics I
Experimental Therapeutics I Mary Hitt 5142 Katz Group Centre mhitt@ualberta.ca; or Mary.Hitt@albertahealthservices.ca 1 Specific Topics for Today Preclinical and clinical testing Gene therapy Nonviral
More informationRecombinant adeno-associated virus vectors induce functionally impaired transgene product specific CD8 + T cells in mice
Research article Recombinant adeno-associated virus vectors induce functionally impaired transgene product specific CD8 + T cells in mice Shih-Wen Lin, 1,2 Scott E. Hensley, 1,2 Nia Tatsis, 2 Marcio O.
More informationChapter 4 Neuronal Physiology
Chapter 4 Neuronal Physiology V edit. Pg. 99-131 VI edit. Pg. 85-113 VII edit. Pg. 87-113 Input Zone Dendrites and Cell body Nucleus Trigger Zone Axon hillock Conducting Zone Axon (may be from 1mm to more
More informationPositron Emission Tomography: Tool to Facilitate Drug Development and to Study Pharmacokinetics
Positron Emission Tomography: Tool to Facilitate Drug Development and to Study Pharmacokinetics Robert B. Innis, MD, PhD Molecular Imaging Branch National Institute Mental Health 1 Outline of Talk 1. PET
More informationThird line of Defense. Topic 8 Specific Immunity (adaptive) (18) 3 rd Line = Prophylaxis via Immunization!
Topic 8 Specific Immunity (adaptive) (18) Topics - 3 rd Line of Defense - B cells - T cells - Specific Immunities 1 3 rd Line = Prophylaxis via Immunization! (a) A painting of Edward Jenner depicts a cow
More informationSynaptic Communication. Steven McLoon Department of Neuroscience University of Minnesota
Synaptic Communication Steven McLoon Department of Neuroscience University of Minnesota 1 Course News The first exam is next week on Friday! Be sure to checkout the sample exam on the course website. 2
More informationAviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES
Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES October 30, 2017 Safe Harbor This presentation contains forward-looking statements about
More informationPositron Emission Tomography: Tool to Facilitate Drug Development and to Study Pharmacokinetics
Positron Emission Tomography: Tool to Facilitate Drug Development and to Study Pharmacokinetics Robert B. Innis, MD, PhD Molecular Imaging Branch National Institute Mental Health 1 Outline of Talk 1. PET
More informationZheng, BJ; Du, LY; Zhao, GY; Lin, YP; Sui, HY; Chan, C; Ma, S; Guan, Y; Yuen, KY. Citation Hong Kong Medical Journal, 2008, v. 14 suppl. 4, p.
Title Studies of SARS virus vaccines Author(s) Zheng, BJ; Du, LY; Zhao, GY; Lin, YP; Sui, HY; Chan, C; Ma, S; Guan, Y; Yuen, KY Citation Hong Kong Medical Journal, 2008, v. 14 suppl. 4, p. 39-43 Issued
More informationGSK VACCINES: BUILDING A THERAPEUTIC PORTFOLIO
GSK VACCINES: BUILDING A THERAPEUTIC PORTFOLIO Vincent Brichard, MD Vice President & Head of Immunotherapeutics, GSK Biologicals Immunotherapy in action Cytolytic T Lymphocyte (CTL) Tumour cell Killed
More informationAnatomy Review. Graphics are used with permission of: Pearson Education Inc., publishing as Benjamin Cummings (
Anatomy Review Graphics are used with permission of: Pearson Education Inc., publishing as Benjamin Cummings (http://www.aw-bc.com) Page 1. Introduction Neurons communicate with other cells at junctions
More informationThe Role of Smoking in Cocaine. Addiction
The Role of Smoking in Cocaine Addiction Luca Colnaghi Eric Kandel Laboratory Columbia University in the City of New York Department of Neuroscience Index 1- The Brain, memory, metaplasticity 2- Cocaine
More informationAfrican American Men and Prostate Cancer Management Option for Clinical PROSPECT Trial Participation in an Immunotherapy Study
African American Men and Prostate Cancer Management Option for Clinical PROSPECT Trial Participation in an Immunotherapy Study Jennifer Harris, PharmD Medical Science Liaison Bavarian Nordic, Inc. Prostate
More informationSupporting Information
Supporting Information Horwitz et al. 73/pnas.35295 A Copies ml - C 3NC7 7 697 698 7 7 73 76-2 2 Days Gp2 residue G458D G459D T278A 7/36 N28 K D 28 459 A28T ID# 697 ID# 698 ID# 7 ID# 7 ID# 73 ID# 76 ID#
More informationThe humoral immune responses to IBV proteins.
The humoral immune responses to IBV proteins. E. Dan Heller and Rosa Meir The Hebrew University of Jerusalem, Israel COST FA1207 meeting WG2 + WG3, Budapest, Jan. 2015 1 IBV encodes four major structural
More informationCorporate Medical Policy
Corporate Medical Policy Voretigene Neparvovec-rzyl (Luxturna) File Name: Origination: Last CAP Review: Next CAP Review: Last Review: voretigene_neparvovec_rzyl_luxturna 1/2018 N/A 6/2018 2/2018 Description
More informationThe Reduction of the Demand of Nicotine Due to Pregabalin and Gabapentin: Two Cases ME Ceylan 1, A Evrensel 1, BÖ Ünsalver 1, G Cömert 2 ABSTRACT
The Reduction of the Demand of Nicotine Due to Pregabalin and Gabapentin: Two Cases ME Ceylan 1, A Evrensel 1, BÖ Ünsalver 1, G Cömert 2 ABSTRACT Pregabalin and gabapentin, it s pharmacological like drug
More informationPhysical and Physiological Aspects of Drug Use and Abuse
Question 1: What are neurons and neurotransmitters? Answer 1: A neuron is a nerve cell. It is estimated that there are 100 billion neurons in the average human brain (Levinthal, 2008). Neurons receive
More informationFoot and Mouth Disease Control, A vaccine perspective. John Barlow, DVM PhD
Foot and Mouth Disease Control, A vaccine perspective John Barlow, DVM PhD john.barlow@uvm.edu May 28, 2015 Countries in which FMD was reported to the OIE between 1990 and 2002 Antigenic variation is common
More informationRNAi in HBV, the next backbone therapy for use in combinations? Bruce D. Given, MD COO, Arrowhead Pharmaceuticals L.I.F.E.R.
RNAi in HBV, the next backbone therapy for use in combinations? Bruce D. Given, MD COO, Arrowhead Pharmaceuticals L.I.F.E.R. October 20, 2017 Safe Harbor Statement This presentation contains forward-looking
More informationOncolytic Virotherapy Summit Novel stroma targeted and microenvironment-inducible oncolytic adenoviruses (OAVs)
Oncolytic Virotherapy Summit 2016 Novel stroma targeted and microenvironment-inducible oncolytic adenoviruses (OAVs) Osvaldo L. Podhajcer, Ph.D. Superior Researcher CONICET (Consejo Nacional de Investigaciones
More informationComments made today contain forward looking statements as described under the Private Securities Litigation Reform Act of Our forward looking
EBOLA HIV January 2015 Comments made today contain forward looking statements as described under the Private Securities Litigation Reform Act of 1995. Our forward looking statements represent our current
More informationClassroom Tested Lesson
Classroom Tested Lesson Video Description Secrets of the Sequence, Show 151, Episode 2 Quick Fix Smoking in the Genes approximately 9 minutes viewing time Why do some smokers become addicted to nicotine
More informationVector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys
Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys Philip R Johnson, Bruce C Schnepp, Jianchao Zhang, Mary J Connell, Sean M Greene,
More informationLETERMOVIR (MK-8228): OVERVIEW OF PIVOTAL PHASE 3 STUDY (P001) ASSESSING PROPHYLAXIS OF LETERMOVIR VS. PLACEBO IN ALLOGENEIC HSCT RECIPIENTS
LETERMOVIR (MK-8228): OVERVIEW OF PIVOTAL PHASE 3 STUDY (P001) ASSESSING PROPHYLAXIS OF LETERMOVIR VS. PLACEBO IN ALLOGENEIC HSCT RECIPIENTS October 6, 2017 Cyrus Badshah, MD, PhD Director, Clinical Research
More informationGlobal progress in vaccine development
Global progress in vaccine development Helen McShane The Jenner Institute University of Oxford helen.mcshane@ndm.ox.ac.uk Vaccination The most cost-effective health intervention Smallpox Poliomyelitis
More informationNeurochemistry 2. Loewi s experiment
Neurochemistry 2 Loewi s experiment Cengage Learning 2016 AP reaches the axon terminal and activates voltage-gated Ca++ channels (3 major classes). Ca++ influx results in exocytosis of neurotransmitters
More informationBody control systems. Nervous system. Organization of Nervous Systems. The Nervous System. Two types of cells. Organization of Nervous System
Body control systems Nervous system Nervous system Quick Sends message directly to target organ Endocrine system Sends a hormone as a messenger to the target organ Slower acting Longer lasting response
More informationImmunity and Infection. Chapter 17
Immunity and Infection Chapter 17 The Chain of Infection Transmitted through a chain of infection (six links) Pathogen: Disease causing microorganism Reservoir: Natural environment of the pathogen Portal
More informationDiseases caused by Smoking
Name: Class: Date: Diseases caused by Smoking Biology Gr11A Diseases caused by Smoking Unless you're living in a cave under the heart of Kentucky tobacco country, you know that smoking isn't exactly the
More informationHuman Immunodeficiency Virus
Human Immunodeficiency Virus Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Viruses and hosts Lentivirus from Latin lentis (slow), for slow progression of disease
More informationAddictions Pharmacotherapy
Addictions Pharmacotherapy Thomas Kosten MD Associate Vice President for Research JH Waggoner Chair & Professor of Psychiatry, Pharmacology & Neuroscience Baylor College of Medicine Disclosure Thomas Kosten,
More informationDevelopment of a Recombinant Subunit Dengue Vaccine. Flavivirus Vaccination Fondation Mérieux December 8, 2010 Beth-Ann Coller
Development of a Recombinant Subunit Dengue Vaccine Flavivirus Vaccination Fondation Mérieux December 8, 2010 Beth-Ann Coller Recombinant Subunit Dengue Vaccine Recombinant Envelope Protein Vaccine Hawaii
More informationTobacco Dependence: Assessment and Treatment. Douglas Arenberg
Tobacco Dependence: Assessment and Treatment Douglas Arenberg Disclosure MDCH Grant Funds to improve tobacco cessation service in the Michigan Medicine Health System Past paid service Consultant/Advisory
More informationBIT 120. Copy of Cancer/HIV Lecture
BIT 120 Copy of Cancer/HIV Lecture Cancer DEFINITION Any abnormal growth of cells that has malignant potential i.e.. Leukemia Uncontrolled mitosis in WBC Genetic disease caused by an accumulation of mutations
More informationSolution key Problem Set
Solution key- 7.013 Problem Set 6-2013 Question 1 a) Our immune system is comprised of different cell types. Complete the table below by selecting all correct cell types from the choices provided. Cells
More informationPharmacogenetic Approaches to the Treatment of Alcoholism: Preclinical Studies
Pharmacogenetic Approaches to the Treatment of Alcoholism: Preclinical Studies Dr. Yedy Israel Departament of Pharmacological and Toxicological Chemistry and Programme of Molecular and Clinical Pharmacology
More informationEmerging Respiratory Viruses: Challenges and Vaccine Strategies
CLINICAL MICROBIOLOGY REVIEWS, Oct. 2006, p. 614 636 Vol. 19, No. 4 0893-8512/06/$08.00 0 doi:10.1128/cmr.00005-06 Emerging Respiratory Viruses: Challenges and Vaccine Strategies Laura Gillim-Ross and
More informationLa risposta immune all infezione da virus ebola. Chiara Agrati, PhD
La risposta immune all infezione da virus ebola Chiara Agrati, PhD Pathogenetic mechanisms This virus infection is able to: - disable the immune system, preventing an effective protective immune response
More informationCRN 24-mo final report
CRN 24-mo final report Gene transfer studies for cystinosis Principal investigator: Vasiliki Kalatzis, Ph.D. Co-investigator: Eric J. Kremer, Ph.D. Affiliation: Institut Génétique Moléculaire de Montpellier
More informationGeneral Functions (3) 1.Sensory gathers information 2.Integrative information is brought together 3.Motor responds to signals, homeostasis
Nervous System Responsible for being aware of the world, coordinating body functions and maintaining homeostasis Information from inside and outside the body is brought to the brain and spinal cord, stimulating
More informationPreclinical Psychopharmacology: From Mechanisms & Molecules to Medicines
Preclinical Psychopharmacology: From Mechanisms & Molecules to Medicines Pradeep G. Bhide, Ph.D. Rodgers Eminent Scholar Chair of Developmental Neuroscience Director, Center for Brain Repair Florida State
More informationDISEASES / IMMUNOLOGY
QUESTIONSHEET 1 Immunity can be defined as the ability to resist infection. (a) A person can acquire immunity actively or passively. Complete the table to show some of the features of passive and active
More informationBIOL Week 6. Nervous System. Transmission at Synapses
Collin County Community College BIOL 2401 Week 6 Nervous System 1 Transmission at Synapses Synapses are the site of communication between 2 or more neurons. It mediates the transfer of information and
More informationState of the Science in the treatment of nicotine dependence Terry A. Rustin, M.D.
State of the Science in the treatment of nicotine dependence 2006 Terry A. Rustin, M.D. State of the Science Public health issues Effects of nicotine Smoking cessation New chemotherapeutic agents Nicotine
More informationTranscriptional and Epigenetic Mechanisms of Addiction
Transcriptional and Epigenetic Mechanisms of Addiction Eric J. Nestler Mount Sinai School of Medicine New York, NY Dr. Ray Fuller There is every reason to be optimistic that in the future we will find
More informationA Refined Approach to Producing Polyclonal Antibodies in Chickens
A Refined Approach to Producing Polyclonal Antibodies in Chickens Completely Replacing All Invasive Elements by Combining Immunizations with Routine Aerosol-based Vaccinations Otto Kalliokoski, Department
More informationIntegrin v 3 targeted therapy for Kaposi s sarcoma with an in vitro evolved antibody 1
Integrin v 3 targeted therapy for Kaposi s sarcoma with an in vitro evolved antibody 1 CHRISTOPH RADER, 2 MIKHAIL POPKOV, JOHN A. NEVES, AND CARLOS F. BARBAS III 2 Department of Molecular Biology and The
More informationLow Dopamine Receptor Availability May Promote Cocaine Addiction
of 5 10/10/2011 10:56 AM NIDA NEWS NIDA Home > Publications > NIDA Notes > Vol. 22, No. 3 > Research Findings Low Dopamine Receptor Availability May Promote Cocaine Addiction Research Findings Vol. 22,
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/35908 holds various files of this Leiden University dissertation Author: Soema, Peter Title: Formulation of influenza T cell peptides : in search of a universal
More informationاهتحانات الشهادة الثانىية العاهة فرع علىم الحياة هسابقة في هادة علىم الحياة الودة: ثالث ساعات
وزارة التربية والتعلين العالي الوديرية العاهة للتربية دائرة االهتحانات اهتحانات الشهادة الثانىية العاهة فرع علىم الحياة هسابقة في هادة علىم الحياة الودة: ثالث ساعات االسن: الرقن: دورة سنة 2009 العادية
More informationNo! No! No! No! With the possible exception of humans Public Health Question Does the compound have the potential to be abused? Public Health Question Does the compound have the potential to be abused?
More informationUNIVERSAL INFLUENZA VIRUS VACCINES Adolfo García Sastre. Icahn School of Medicine at Mount Sinai, New York
UNIVERSAL INFLUENZA VIRUS VACCINES Adolfo García Sastre Icahn School of Medicine at Mount Sinai, New York INFLUENZA VIRUSES PAx B EPIDEMIOLOGY OF HUMAN INFLUENZA VIRUSES A H1N1 H3N2 1968 H2N2 1957 H1N1
More information